- Dubois seeks legitimacy with Joshua scalp
- Rate cut could lift consumer spirits before US elections
- Last-gasp Gimenez strike sends Atletico past Leipzig
- Barca stumble at Monaco after early red card
- Raya heroics save Arsenal in Champions League opener at Atalanta
- Guardians beat Twins to secure MLB playoff berth
- Jihadist attack in Mali capital killed more than 70: security sources
- Alonso hails 'efficient' Leverkusen after Feyenoord rout
- Ex-Man United striker Anthony Martial joins AEK Athens
- NFL unbeatens meet as Texans visit Vikings, Steelers host Chargers
- Head's hundred seals Australia win over England in 1st ODI after Labuschagne strikes
- Dream debut for Wirtz as Leverkusen thump dire Feyenoord
- Myanmar flood death toll climbs to 293: state media
- Israel army says West Bank air strike kills 4 militants
- LIV golfers get green light for US Ryder Cup team, PGA Championship
- US accuses social media giants of 'vast surveillance'
- Ten Hag to bed Hojlund, Mount in carefully when they return for Man Utd
- Breaking bad as McIlroy endures 'weird' day
- EU chief announces $11 bn for nations hit by 'heartbreaking' floods
- Spanish PM, Palestinian leader urge Mideast de-escalation
- New study reinforces theory Covid emerged at Chinese market
- World Bank boosts climate financing by 10 percent
- Bagnaia eyeing summit on home ground in 100th MotoGP
- 'Something was wrong', defendant in French mass rape tells court
- Hezbollah chief admits 'unprecedented' blow in device blasts
- Sales of US existing homes slip slightly in August
- Fear, panic haunt Lebanese after devices explode
- Labuschagne sparks Australia fightback in England ODI opener
- S.Africa's HIV research power couple says fight goes on
- Why is Israel focusing on border with Lebanon?
- Mpox vaccines administered in Rwanda, first in Africa
- US Fed rate cut is 'very positive sign' for economy: Yellen
- Unknown Mozart string trio discovered in Germany
- 'Are we five-year-olds?' F1 drivers won't mind their language
- Brazil judge orders X to reimpose block or face hefty fine
- Munich to rename stadium street after Beckenbauer
- Champions Italy to face Argentina in Davis Cup Final 8
- The winding, fitful path to weight loss drug Ozempic
- Italians defeat American Magic to reach Louis Vuitton Cup final
- Norris has 'nothing to lose' as he hunts Verstappen in Singapore
- Kyiv 'outraged' at Swiss showing of Russian war film
- French city renames Abbe Pierre square after abuse claims
- Footballer charged after huge cannabis seizure at UK airport
- Vatican recognises Medjugorje shrine, but not Virgin's messages
- Bank of England freezes rate after jumbo US cut
- Playing Nadal is 'kind of a nightmare', says Alcaraz
- Portugal tackles last of deadly northern forest fires
- Ton-up Ashwin lifts India to 339-6 against Bangladesh
- Departing NATO chief warns US against 'isolationism'
- Coming winter 'sternest test yet' for Ukraine energy grid
French-Canadian gets 'Oscars of Science' prize for cancer treatment
French-Canadian scientist Michel Sadelain was awarded an "Oscars of Science" prize in Los Angeles on Saturday for his research into genetically modifying immune cells to fight cancer.
The genetic engineer was awarded the Breakthrough Prize at a glitzy ceremony attended by tech giants such as Elon Musk and Bill Gates, and an array of celebrities including Jessica Chastain, Robert Downey Jr. and Bradley Cooper.
His work has led to the development of a new form of therapy called CAR-T that has shown exceptional efficacy against certain blood cancers.
"This prize is an extraordinary recognition," Sadelain told AFP on the red carpet at the Oscars Museum. "It's all the more of an honor because ... my scientific colleagues told me for a long time that it would never work."
Launched in 2010, the Breakthrough Prize awards "the world's most brilliant minds" in fields including life sciences, fundamental physics and mathematics, styling itself as the Silicon Valley-backed answer to the Nobels.
Dubbed the "Oscars for Science", founding sponsors include Sergey Brin, Priscilla Chan and Mark Zuckerberg.
Sadelain will split the $3 million prize money with American immunologist Carl June, who also led groundbreaking research into the field independently of his co-winner.
"The greatest pleasure, however, is to see patients... who no longer had a chance and who thank us, who are alive today thanks to CAR-T cells," said Sadelain.
Sadelain studied medicine in Paris, then immunology in Canada, before taking up postdoctoral research at the Massachusetts Institute of Technology in 1989.
- 'Living drugs' -
At the time, there was great interest in developing vaccines to train the immune system to recognize and destroy cancer cells, in the same way it can be taught to tackle foreign invaders such as bacteria and viruses.
After moving to the Memorial Sloan Kettering Cancer Center in New York, Sadelain developed a way to use a disabled virus to genetically reprogram human T-cells, so that they grew claw-like structures called antigen receptors, allowing the T-cells to target specific cancer cells.
Beyond recognizing the cancer, these Chimeric Antigen Receptor (CAR) T-cells, as Sadelain named them, were also given genetic instructions to enter a killing mode and to multiply, growing an army inside the body to eliminate the enemy.
Thanks to the groundwork laid by Sadelain and June, half a dozen US-approved CAR-T cell therapies are now available, and hundreds more trials are underway.
Patients' own T-cells are collected, modified outside the body, and then infused back into the blood, creating so-called "living drugs".
The treatment has proved effective against lymphoma, certain leukaemias and myeloma, a serious and complex blood cancer. Sadelain hopes that research will make it possible to "apply this treatment to other cancers".
One of the main challenges is to lower the cost of treatment, which costs over $500,000 -- a sum generally covered by insurance.
Around 20 other scientists were honored on Saturday at the Breakthrough Prize, in various categories.
Some of the research awarded included effective drugs to treat the underlying cause of cystic fibrosis, a genetic disorder that affects the lungs, and the discovery of the most common genetic causes of Parkinson's disease.
A.Motta--PC